Raul Uppot (Massachusetts General Hospital, Boston, USA) speaks to Interventional News about the evolution of hepatic ablation, following his talk on the same topic at the recent Symposium on Clinical Interventional Oncology (CIO).
He says: “What I want people to know is that liver ablation started off as a small trial: can we kill a tumour with a small needle? Over the past 30 years, we have shown that that is possible. It is exciting that, using a small probe, you can insert it into the liver and impact care—completely treat large tumours, multiple tumours, and yet the patient goes home as an outpatient with just a band-aid. The ability to do great oncological care and work with a small needle is exciting about ablation.”
You can read a report of the full interview here.